Patents by Inventor Guiqun YANG

Guiqun YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS
    Publication number: 20230128198
    Abstract: Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.
    Type: Application
    Filed: January 22, 2021
    Publication date: April 27, 2023
    Inventors: Dai CHENG, Mingming CHEN, Amin LI, Haijun LI, Guiqun YANG
  • Tricyclic compounds
    Patent number: 11466005
    Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: October 11, 2022
    Assignee: JACOBIO PHARMACEUTICALS CO., LTD.
    Inventors: Haiquan Fang, Mingming Chen, Guiqun Yang, Yuelei Du, Yanping Wang, Tong Wu, Qinglong Li, Lei Zhang, Shaojing Hu
  • Heterocyclic compounds useful as aurora a selective inhibitors
    Patent number: 11384066
    Abstract: Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: July 12, 2022
    Assignee: Jacobio Pharmaceuticals Co., Ltd.
    Inventors: Dai Cheng, Mingming Chen, Amin Li, Haijun Li, Guiqun Yang
  • TRICYCLIC COMPOUNDS
    Publication number: 20220119390
    Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 21, 2022
    Inventors: Haiquan FANG, Mingming CHEN, Guiqun YANG, Yuelei DU, Yanping WANG, Tong WU, Qinglong LI, Lei ZHANG, Shaojing HU
  • BINDING MOLECULE SPECIFIC FOR LIF AND USE THEREOF
    Publication number: 20210403582
    Abstract: Provided is a binding molecule specific for LIF and use thereof. Specifically, provided is an isolated antibody or an antigen-binding fragment thereof that binds to LIF and inhibits the activity of LIF. Also provided are uses of the isolated antibody or the antigen-binding fragment thereof in treatment of diseases.
    Type: Application
    Filed: August 20, 2021
    Publication date: December 30, 2021
    Inventors: Qinghao LIU, Jun TAO, Wenlai ZHOU, Shanshan HE, Haiyan YANG, Hongling WANG, Guiqun YANG
  • TRICYCLIC COMPOUNDS
    Publication number: 20210179617
    Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 17, 2021
    Inventors: Haiquan FANG, Mingming CHEN, Guiqun YANG, Yuelei DU, Yanping WANG, Tong WU, Qinglong LI, Lei ZHANG, Shaojing HU